Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 54, Issue 9, Pages 1134-1149
Publisher
Wiley
Online
2021-09-30
DOI
10.1111/apt.16611
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
- (2020) Fiona van den Berg et al. Viruses-Basel
- Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection
- (2020) Kazuharu Suzuki et al. JOURNAL OF GASTROENTEROLOGY
- Countdown to 2030: eliminating hepatitis B disease, China
- (2019) Jue Liu et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
- (2019) Patrick Marcellin et al. LIVER INTERNATIONAL
- Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine and Pediatrics
- (2019) Christopher R. Shuhart et al. JOURNAL OF CLINICAL DENSITOMETRY
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic strategies for hepatitis B virus infection: towards a cure
- (2019) Gregory C. Fanning et al. NATURE REVIEWS DRUG DISCOVERY
- Systematic review: chronic viral hepatitis and metabolic derangement
- (2019) Chia-Chi Wang et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Changes in Body Mass Index and Atherosclerotic Disease Risk Score after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
- (2019) Jason J Schafer et al. Open Forum Infectious Diseases
- Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B
- (2018) G. L.-H. Wong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- How to improve access to therapy in hepatitis B patients
- (2018) Miroslava Subic et al. LIVER INTERNATIONAL
- A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
- (2018) Mario Gomez et al. INFECTION
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- The ProTide Prodrug Technology: From the Concept to the Clinic
- (2017) Youcef Mehellou et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese PopulationClinical Perspective
- (2016) Xueli Yang et al. CIRCULATION
- Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study
- (2016) Jia Yao et al. NUTRITION
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
- (2015) S. K. Sarin et al. Hepatology International
- Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD
- (2015) John A. Shepherd et al. JOURNAL OF CLINICAL DENSITOMETRY
- Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
- (2015) Todd T. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
- (2015) Paul E Sax et al. LANCET
- Association Between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis
- (2015) Chien-Hua Chen et al. MEDICINE
- Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
- (2015) Jose I Bernardino et al. Lancet HIV
- Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal
- (2014) Mauro Viganò et al. JOURNAL OF CLINICAL VIROLOGY
- Tenofovir disoproxil fumaratevsadefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial
- (2014) J. L. Hou et al. JOURNAL OF VIRAL HEPATITIS
- Hepatitis B virus infection
- (2014) Christian Trépo et al. LANCET
- Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection
- (2013) David M Gracey et al. ANTIVIRAL THERAPY
- Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy
- (2012) Cheng-Yuan Peng et al. JOURNAL OF HEPATOLOGY
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
- (2012) Patrick Marcellin et al. LANCET
- Lipid parameters for measuring risk of cardiovascular disease
- (2011) Benoit J. Arsenault et al. Nature Reviews Cardiology
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
- (2009) Daniel J. Tenney et al. HEPATOLOGY
- Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents
- (2008) C. Berger et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks
- (2008) Morris Sherman et al. HEPATOLOGY
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
- (2008) Patrick Marcellin et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started